Enzyme Defects and Immune Dysfunction
Published on 16. September 2009
384 pages
978-0-470-71819-3 (ISBN)
Description
The Novartis Foundation Series is a popular collection of the proceedings from Novartis Foundation Symposia, in which groups of leading scientists from a range of topics across biology, chemistry and medicine assembled to present papers and discuss results. The Novartis Foundation, originally known as the Ciba Foundation, is well known to scientists and clinicians around the world.
More details
Other editions
Additional editions
Software
05/2008
Wiley
€82.61
No shipping information available
Book
12/1979
Wiley
Unfortunately, price unknown
Withdrawn from sale
Persons
Katherine Elliott is the editor of Enzyme Defects and Immune Dysfunction, published by Wiley.
Julie Whelan is the editor of Enzyme Defects and Immune Dysfunction, published by Wiley.
Content
1 - Enzyme Defects and Immune Dysfunction [Seite 5]
1.1 - Contents [Seite 7]
1.1.1 - Chairman's introduction [Seite 13]
1.1.2 - Adenosine deaminase and purine nucleoside phosphorylase deficiency: how they were discovered and what they may mean [Seite 15]
1.1.2.1 - Discussion [Seite 25]
1.1.3 - Buridan's ass: one man's view of the immune system [Seite 31]
1.1.3.1 - Discussion [Seite 40]
1.1.4 - Clinical delineation of adenosine deaminase deficiency [Seite 47]
1.1.4.1 - Discussion [Seite 61]
1.1.5 - Immunological aberrations in purine nucleoside phosphorylase deficiencies [Seite 67]
1.1.5.1 - Discussion [Seite 81]
1.1.6 - Immunodeficiency due to transcobalamin II deficiency [Seite 89]
1.1.6.1 - Discussion [Seite 100]
1.1.7 - General Discussion I Model systems for study of enzyme deficiencies [Seite 105]
1.1.8 - Nucleotide metabolism in cultured T cells and in cells of patients deficient in adenosine deaminase and purine nucleoside phosphorylase [Seite 113]
1.1.8.1 - Discussion [Seite 117]
1.1.9 - Deoxyribonucleoside toxicity in adenosine deaminase and purine nucleoside phosphorylase deficiency: implications for the development of new immunosuppressive agents [Seite 127]
1.1.9.1 - Discussion [Seite 136]
1.1.10 - Ecto 5'-nucleotidase deficiency in primary hypogammaglobulinaemia [Seite 147]
1.1.10.1 - Discussion [Seite 156]
1.1.11 - General Discussion II The methylation hypothesis of adenosine toxicity [Seite 165]
1.1.11.1 - Enzymology of immunodeficiency states [Seite 171]
1.1.12 - Allosteric regulation of calf thymus ribonucleotide reductase [Seite 177]
1.1.12.1 - Discussion [Seite 184]
1.1.13 - Adenosine deaminase: characteristics of the normal and mutant forms of the human enzyme [Seite 189]
1.1.13.1 - Discussion [Seite 198]
1.1.14 - Purine nucleoside phosphorylase: the normal enzyme and structural alterations in immunodeficiency disease [Seite 205]
1.1.14.1 - Discussion [Seite 214]
1.1.15 - Purine nucleoside phosphorylase : immunodetection and characterization of the human enzyme [Seite 219]
1.1.16 - Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency [Seite 225]
1.1.16.1 - Discussion [Seite 235]
1.1.17 - An approach to the restoration of T cell function in a purine nucleoside phosphorylase deficient patient [Seite 243]
1.1.17.1 - Discussion [Seite 259]
1.1.18 - Purine metabolism in adenosine deaminase deficiency [Seite 267]
1.1.19 - Final General Discussion Selective treatment of lymphoid malignancy with adenosine deaminase inhibitors [Seite 275]
1.1.19.1 - Defects in differentiation underlying ADA and PNP deficiency [Seite 284]
1.1.19.2 - Search for new enzyme deficiencies [Seite 288]
1.1.20 - Index of contributors [Seite 293]
1.1.21 - Subject index [Seite 295]
1.1 - Contents [Seite 7]
1.1.1 - Chairman's introduction [Seite 13]
1.1.2 - Adenosine deaminase and purine nucleoside phosphorylase deficiency: how they were discovered and what they may mean [Seite 15]
1.1.2.1 - Discussion [Seite 25]
1.1.3 - Buridan's ass: one man's view of the immune system [Seite 31]
1.1.3.1 - Discussion [Seite 40]
1.1.4 - Clinical delineation of adenosine deaminase deficiency [Seite 47]
1.1.4.1 - Discussion [Seite 61]
1.1.5 - Immunological aberrations in purine nucleoside phosphorylase deficiencies [Seite 67]
1.1.5.1 - Discussion [Seite 81]
1.1.6 - Immunodeficiency due to transcobalamin II deficiency [Seite 89]
1.1.6.1 - Discussion [Seite 100]
1.1.7 - General Discussion I Model systems for study of enzyme deficiencies [Seite 105]
1.1.8 - Nucleotide metabolism in cultured T cells and in cells of patients deficient in adenosine deaminase and purine nucleoside phosphorylase [Seite 113]
1.1.8.1 - Discussion [Seite 117]
1.1.9 - Deoxyribonucleoside toxicity in adenosine deaminase and purine nucleoside phosphorylase deficiency: implications for the development of new immunosuppressive agents [Seite 127]
1.1.9.1 - Discussion [Seite 136]
1.1.10 - Ecto 5'-nucleotidase deficiency in primary hypogammaglobulinaemia [Seite 147]
1.1.10.1 - Discussion [Seite 156]
1.1.11 - General Discussion II The methylation hypothesis of adenosine toxicity [Seite 165]
1.1.11.1 - Enzymology of immunodeficiency states [Seite 171]
1.1.12 - Allosteric regulation of calf thymus ribonucleotide reductase [Seite 177]
1.1.12.1 - Discussion [Seite 184]
1.1.13 - Adenosine deaminase: characteristics of the normal and mutant forms of the human enzyme [Seite 189]
1.1.13.1 - Discussion [Seite 198]
1.1.14 - Purine nucleoside phosphorylase: the normal enzyme and structural alterations in immunodeficiency disease [Seite 205]
1.1.14.1 - Discussion [Seite 214]
1.1.15 - Purine nucleoside phosphorylase : immunodetection and characterization of the human enzyme [Seite 219]
1.1.16 - Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency [Seite 225]
1.1.16.1 - Discussion [Seite 235]
1.1.17 - An approach to the restoration of T cell function in a purine nucleoside phosphorylase deficient patient [Seite 243]
1.1.17.1 - Discussion [Seite 259]
1.1.18 - Purine metabolism in adenosine deaminase deficiency [Seite 267]
1.1.19 - Final General Discussion Selective treatment of lymphoid malignancy with adenosine deaminase inhibitors [Seite 275]
1.1.19.1 - Defects in differentiation underlying ADA and PNP deficiency [Seite 284]
1.1.19.2 - Search for new enzyme deficiencies [Seite 288]
1.1.20 - Index of contributors [Seite 293]
1.1.21 - Subject index [Seite 295]
